Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Clinical Trial of STAHIST in Seasonal Allergic Rhinitis Patients

This study has been completed.
Sponsor:
Information provided by:
Magna Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT00932256
First received: June 30, 2009
Last updated: December 6, 2010
Last verified: December 2010

June 30, 2009
December 6, 2010
October 2009
October 2009   (final data collection date for primary outcome measure)
To gather pharmacodynamic measurements and assess blood levels (five draws) of the active ingredients in STAHIST over the dosage interval period of 12 hours. [ Time Frame: August 2009 ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT00932256 on ClinicalTrials.gov Archive Site
To report any side effects or adverse drug reactions and rate the severity of incidence. [ Time Frame: August 2009 ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Clinical Trial of STAHIST in Seasonal Allergic Rhinitis Patients
STAHIST IND 105781 Phase 1 Clinical Trial

MAGNA intends to show that the combination of pseudoephedrine, chlorpheniramine, plus a small amount of belladonna alkaloid is a comprehensive, safe and effective twice daily (BID) drug treatment for seasonal allergic rhinitis (SAR) patients with post-nasal drip (PND). The phase 1 single-dose trial will consist of 21 subjects: 1) to gather pharmacodynamic measurements and blood levels of active ingredients over 12 hours; 2) To report subjective scores by subjects rating efficacy of single dose of STAHIST; 3) To report any side effects or adverse drug reactions and rate the severity of incidence.

No procedure will be performed until Informed Consent has been obtained. Inclusion and exclusion criteria will be verified. Subjects will be required to stop using oral nasal decongestants or first generation antihistamines for 48 hours, second generation antihistamines and Singulair for seven days, systemic corticosteroids for 30 days, and nasal or ocular corticosteroid medications for two weeks. Use of these drugs will not be allowed during the study.

Blood samples will be drawn at specific time points: baseline fasting blood draw just before 7AM, then at 9 AM, 11AM, 3PM, and 7PM. A single oral dose of STAHIST will be administered at 7AM.

During the study a diary of the five study symptoms (S5 Diary) will be scored hourly over the 12-hour period as follows: 0 none, 1 mild, 2 moderate, 3 severe. The S5 symptoms are 1. Nasal Congestion (Stuffiness); 2. Sneezing; 3. Rhinorrhea (runny nose); 4. Nasal Itching; 5. Post-nasal drip. Post nasal drip is defined for the patient as "you can feel accumulated mucus dripping down the back of your throat from your sinuses, also possibly including a tickly cough or sore throat due to this sensation of mucus."

Side effects or adverse drug reactions will be scored if they occur and hourly as 1 mild, 2 moderate, and 3 severe. Any adverse events will be recorded. Any subject who is not able or who is unwilling to continue keeping a diary or participate in blood draws will be permitted to withdraw from the study. Safety will be assured by the frequent visible assessment and questioning of subjects as well as monitoring of subjects' vital signs by Dr. Pollard and his nursing staff. Subjects will remain in the clinic during the 12-hour dosage interval. Thereafter, Dr. Pollard and selected staff will be on call 24 hours to answer any subject phone calls.

Interventional
Phase 1
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Rhinitis, Allergic, Seasonal
Drug: STAHIST NDC #58407-536-01
Oral tablet containing Pseudoephedrine hydrochloride 90mg, chlorpheniramine maleate 8mg, atropine sulfate .24mg, one tablet BID.
Other Name: STAHIST NDC#58407-536-01
Experimental: STAHIST for seasonal allergic rhinitis
STAHIST for seasonal allergic rhinitis: each white, scored tablet contains pseudoephedrine hydrochloride 90mg, chlorpheniramine maleate 8mg, and atropine sulfate .24mg
Intervention: Drug: STAHIST NDC #58407-536-01
Moffitt EM. Symptomatic management of upper respiratory allergies. J Miss State Med Assoc. 1968 Apr;9(4):159-61. No abstract available.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
21
December 2010
October 2009   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Males and females of any ethnic group between the ages of 18 and 60 years of age.
  • History of moderate to severe SAR for at least one year.
  • Subjects' symptoms will include the five symptoms ("S5") that are the focus of this study:

    • nasal congestion;
    • rhinorrhea;
    • nasal itching;
    • sneezing;
    • post nasal drip.
  • Prior to study subjects' good health will be confirmed by medical history and physical examination.
  • Allergic hypersensitivity will be confirmed by an appropriate test as deemed necessary by the physician or well established medical history.

Exclusion Criteria:

  • Pregnancy or lactation.
  • Immunotherapy unless at stable maintenance dose.
  • Presence of a medical condition that might interfere with treatment evaluation or require a change in therapy including but not limited to high blood pressure or urinary retention problems.
  • Alcohol dependence.
  • Use of any other investigational drug in the previous month.
  • Subjects presenting with asthma requiring corticosteroid treatment.
  • Subjects with multiple drug allergies.
  • Subjects known to have an idiosyncratic reaction to any of the ingredients in STAHIST.
Both
18 Years to 60 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00932256
STAHIST IND 105781
Yes
Warren P. Lesser, President, MAGNA Pharmaceuticals, Inc.
Magna Pharmaceuticals, Inc.
Not Provided
Principal Investigator: Stephen J Pollard, MD Family Allergy and Asthma Research Institute
Magna Pharmaceuticals, Inc.
December 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP